| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer |
| 13 Oct 2026 |
Form 4: Miller Joseph M, Chief Financial Officer
Granted 200,000 Emplopyee Stock Option (Right to Buy) |
| 13 Oct 2026 |
Form 4: Kozauer Susan Gani, Chief Medical Officer
Granted 200,000 Emplopyee Stock Option (Right to Buy) |
| 13 Oct 2026 | SCHEDULE 13G/A |
| 05 Oct 2026 | EFFECT |
| 01 Oct 2026 | POS AM |
| 01 Oct 2026 | S-3ASR |
| 24 Sep 2026 |
Form 3: Kozauer Susan Gani, Chief Medical Officer
No securities owned |
| 15 Sep 2026 | 424B3 |
| 15 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mu... |
| 14 Sep 2026 |
Form 3: Miller Joseph M, Chief Financial Officer
No securities owned |
| 03 Sep 2026 | 424B3 |
| 03 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mul... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 424B3 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 |
| 03 Aug 2026 |
Form 4: Deep Track Biotechnology Master Fund, Ltd., 10% owner and 2 others
Acquired 286,205 Pre-Funded Warrants (Right to Buy) (Open Market Purchase) ($10M) |
Loading...